All Stories

BMS pushes Fulcrum off its list of partners, scrapping MyoKardia heart muscle pact

Bristol Myers Squibb is levering Fulcrum Therapeutics out of its life. MyoKardia, a biotech BMS bought in 2020, was working with Fulcrum to find cardiomyopathy targets but recently decided to end the alliance.

Mar 5, 2025 - 11:46
 0
BMS pushes Fulcrum off its list of partners, scrapping MyoKardia heart muscle pact
Bristol Myers Squibb is levering Fulcrum Therapeutics out of its life. MyoKardia, a biotech BMS bought in 2020, was working with Fulcrum to find cardiomyopathy targets but recently decided to end the alliance.
Read More

Tags:

Previous Article

L'Oréal sells Carol's Daughter to its founder and an independent entrepreneur

Next Article

Redundancies at Scottish fish farm as business suspends production

Related Posts

Fierce Biotech Fundraising Tracker '25: Callio launches with $187M series A; Eikon's eye-catching $350M series D

Fierce Biotech Fundraising Tracker '25: Callio launches...

Mar 3, 2025  0

Volta Medical’s afib AI shows gains in cardiac ablation study

Volta Medical’s afib AI shows gains in cardiac ablation...

Feb 14, 2025  0

Chutes & Ladders—Neumora overhauls C-suite after phase 3 flop

Chutes & Ladders—Neumora overhauls C-suite after phase ...

Feb 14, 2025  0